Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 14.00 GBp
Change Today +0.125 / 0.90%
Volume 109.7K
SCLP On Other Exchanges
As of 11:35 AM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

scancell holdings plc (SCLP) Snapshot

13.88 GBp
Previous Close
13.88 GBp
Day High
14.00 GBp
Day Low
13.88 GBp
52 Week High
06/1/15 - 44.75 GBp
52 Week Low
11/25/15 - 12.25 GBp
Market Cap
Average Volume 10 Days
-0.01 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for SCANCELL HOLDINGS PLC (SCLP)

Related News

No related news articles were found.

scancell holdings plc (SCLP) Related Businessweek News

No Related Businessweek News Found

scancell holdings plc (SCLP) Details

Scancell Holdings PLC, a biopharmaceutical company, engages in the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer based on its ImmunoBody and Moditope technology platforms in the United Kingdom. It is involved in the development of SCIB1, a plasmid DNA vaccine, which is in I/II clinical trials for the treatment of stage III/IV melanoma; and SCIB2 to treat cancer antigen NY-ESO-1. The company has collaborations with Cancer Research Technology Limited; Immatics Biotechnologies GmbH; NIH; Ichor Medical Systems; and Merck KGaA. Scancell Holdings PLC was incorporated in 2008 and is based in Nottingham, the United Kingdom.

10 Employees
Last Reported Date: 09/18/15
Founded in 2008

scancell holdings plc (SCLP) Top Compensated Officers

Joint Chief Executive Officer, Chief Scientif...
Total Annual Compensation: 10.0K GBP
Joint Chief Executive Officer and Director
Total Annual Compensation: 10.0K GBP
Development Director and Director
Total Annual Compensation: 100.0K GBP
Compensation as of Fiscal Year 2015.

scancell holdings plc (SCLP) Key Developments

Scancell Holdings Plc Announces Executive Appointments

Scancell Holdings Plc announced the appointments of Dr. John Chiplin to the Board of Scancell as a non-executive director, and Dr. Peter Brown as an advisor to the company, with immediate effect. John has significant international experience particularly in the US life science and technology industries. Most recently, John has been instrumental in the NASDAQ Initial Public Offering of Benitec Biopharma, where he has been a Non-Executive Director since 2010. He also serves on the boards of Cynata Therapeutics, Adalta, Batu Biologics, Prophecy, ScienceMedia and the Coma Research Institute. Previously John was President and Chief Executive Officer of Polynoma and from 2006 to 2009 he was Chief Executive Officer of Arana Therapeutics. Peter is a highly experienced pre-clinical and clinical development consultant to the pharmaceutical industry, having most recently served as Vice President & Global Head of Oncology at Teva Pharmaceuticals. Prior to joining Teva, Peter served as Vice President of Clinical Oncology & Experimental Medicine at Cephalon. Here, Peter led the clinical development program for bendamustine and was a key member of the team that completed the NDA submission that led to bendamustine's approval as TREANDA.

Scancell Holdings plc Announces Audited Consolidated Earnings Results for the Year Ended April 30, 2015

Scancell Holdings PLC announced audited consolidated earnings results for the year ended April 30, 2015. For the year, the company's operating loss was GBP 2,959,995 against GBP 2,497,220 a year ago. The increased loss for the period has been as a result of additional expenditure on the SCIB1 clinical trials and the further development of Moditope. Loss before taxation was GBP 2,828,482 against GBP 2,468,034 a year ago. Loss and total comprehensive income was GBP 2,414,630 or 1.07 pence per basic and diluted share against GBP 2,222,954 or 1.03 pence per basic and diluted share a year ago. Net cash used in operating activities was GBP 2,638,747 against GBP 2,093,367 a year ago. Asset acquisition was GBP 22,930 a year ago.

Scancell Holdings PLC, Annual General Meeting, Oct 20, 2015

Scancell Holdings PLC, Annual General Meeting, Oct 20, 2015., at 11:00 GMT Standard Time. Location: Thistle Hotel EMA, East Midlands Airport. Agenda: To approve the adoption of the enclosed reports and financial statements for the year ended 30 April 2015; to consider the re-appointment of Champion Accountants LLP as the company's auditors until next year's Annual General Meeting and to authorise the Directors to set their fees; to consider the permission for the directors to allot further shares; to consider the relaxation of the restrictions which normally apply when ordinary shares are issued for cash; to consider the authority to buy back up to 10% of the company's issued share capital.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCLP:LN 14.00 GBp +0.125

SCLP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SCLP.
View Industry Companies

Industry Analysis


Industry Average

Valuation SCLP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SCANCELL HOLDINGS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at